论文部分内容阅读
目的探讨凯力康治疗急性脑梗死的临床疗效及对血小板功能变化的影响。方法将78例急性脑梗死患者随机分为治疗组和对照组各39例。对照组仅给予临床常规治疗,治疗组在对照组治疗基础上加用凯力康治疗。比较2组的临床疗效及治疗前后血小板(PLT)、血小板平均体积(MPV)、血小板体积分布宽度(PDW)、大血小板比例(P-LCR)水平的变化。结果治疗组基本痊愈率、显效率及总有效率分别为28.2%、38.5%、92.3%,高于对照组的15.4%、17.9%、71.8%;2组治疗后PLT、MPV、PDW、P-LCR水平优于治疗前,且治疗组优于对照组,差异均有统计学意义(P<0.05)。结论凯力康治疗急性脑梗死的临床疗效显著,而且能有效改善患者的血小板功能。
Objective To investigate the clinical efficacy of Keli Kang in the treatment of acute cerebral infarction and its influence on the changes of platelet function. Methods 78 patients with acute cerebral infarction were randomly divided into treatment group and control group, 39 cases each. The control group was given only routine clinical treatment, the treatment group in the control group based on the use of Kai Likang treatment. The clinical efficacy and the changes of platelet (PLT), platelet volume (MPV), platelet volume distribution width (PDW) and the ratio of large platelet (P-LCR) before and after treatment were compared between the two groups. Results The cure rate, effective rate and total effective rate in the treatment group were 28.2%, 38.5% and 92.3% respectively, higher than those in the control group (15.4%, 17.9%, 71.8%). The PLT, MPV, LCR level was better than before treatment, and the treatment group was better than the control group, the differences were statistically significant (P <0.05). Conclusion Keli Kang treatment of acute cerebral infarction significant clinical efficacy, but also can effectively improve the patient’s platelet function.